DE69942454D1 - Hohlraum-induzierte allosterische modifikation von intermolekularen interaktionen und verfahren zur identifikation von verbindungen, die diese bewirken. - Google Patents

Hohlraum-induzierte allosterische modifikation von intermolekularen interaktionen und verfahren zur identifikation von verbindungen, die diese bewirken.

Info

Publication number
DE69942454D1
DE69942454D1 DE69942454T DE69942454T DE69942454D1 DE 69942454 D1 DE69942454 D1 DE 69942454D1 DE 69942454 T DE69942454 T DE 69942454T DE 69942454 T DE69942454 T DE 69942454T DE 69942454 D1 DE69942454 D1 DE 69942454D1
Authority
DE
Germany
Prior art keywords
intermolecular interactions
identifying compounds
modifier
disclosed
hollow
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69942454T
Other languages
English (en)
Inventor
Ramachandran Murali
Mark I Greene
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Application granted granted Critical
Publication of DE69942454D1 publication Critical patent/DE69942454D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Birds (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
DE69942454T 1998-07-01 1999-07-01 Hohlraum-induzierte allosterische modifikation von intermolekularen interaktionen und verfahren zur identifikation von verbindungen, die diese bewirken. Expired - Lifetime DE69942454D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9143198P 1998-07-01 1998-07-01
US13343599P 1999-05-11 1999-05-11
PCT/US1999/015062 WO2000001349A2 (en) 1998-07-01 1999-07-01 Cavity induced allosteric modification of intermolecular interactions and methods of identifying compounds that effect the same

Publications (1)

Publication Number Publication Date
DE69942454D1 true DE69942454D1 (de) 2010-07-15

Family

ID=26783957

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69943308T Expired - Lifetime DE69943308D1 (de) 1998-07-01 1999-07-01 Hohlraum-induzierte allosterische Modifikation von intermolekularen Interaktionen und Verfahren zur Identifikation von Verbindungen, die diese bewirken
DE69942454T Expired - Lifetime DE69942454D1 (de) 1998-07-01 1999-07-01 Hohlraum-induzierte allosterische modifikation von intermolekularen interaktionen und verfahren zur identifikation von verbindungen, die diese bewirken.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69943308T Expired - Lifetime DE69943308D1 (de) 1998-07-01 1999-07-01 Hohlraum-induzierte allosterische Modifikation von intermolekularen Interaktionen und Verfahren zur Identifikation von Verbindungen, die diese bewirken

Country Status (8)

Country Link
US (3) US7653495B1 (de)
EP (2) EP2196930B1 (de)
JP (1) JP4401025B2 (de)
AT (2) ATE503231T1 (de)
AU (1) AU762749B2 (de)
CA (1) CA2336361C (de)
DE (2) DE69943308D1 (de)
WO (1) WO2000001349A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2196930B1 (de) 1998-07-01 2011-03-23 The Trustees of The University of Pennsylvania Hohlraum-induzierte allosterische Modifikation von intermolekularen Interaktionen und Verfahren zur Identifikation von Verbindungen, die diese bewirken
US6673771B1 (en) 1999-07-28 2004-01-06 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclast activity
JP4790179B2 (ja) * 1999-07-28 2011-10-12 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア 破骨細胞活性を阻害する方法
AU2001239725A1 (en) * 2000-01-13 2001-07-24 Tularik, Inc. Antibacterial agents
ATE548031T1 (de) * 2000-12-18 2012-03-15 Inst Med Molecular Design Inc Inhibitoren gegen die produktion und freisetzung entzündungfördernder zytokine
WO2002098420A1 (en) * 2001-06-01 2002-12-12 Cytovia, Inc. 4-substituted-1-(arylmethylidene)thiosemicarbazide, 4-substituted-1-(arylcarbonyl)thiosemicarbazide and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2003028712A2 (en) * 2001-09-28 2003-04-10 Universite Libre De Bruxelles Purinergic and pyrimidinergic receptor agonists for the treatment of activated cd4+ t lymphocyte-mediated immune diseases
EP1574988B1 (de) * 2004-03-08 2014-06-18 Siemens Product Lifecycle Management Software Inc. Bestimmung und Benutzung von geometrischen Merkmalsdaten
JP2007530635A (ja) * 2004-03-29 2007-11-01 ノイロサーチ アクティーゼルスカブ 新規尿素誘導体群およびそれらの利用
EP2298295B1 (de) 2005-01-31 2013-08-28 Cephalon, Inc. Tumornekrosefaktor-Hemmer
US7671058B2 (en) 2006-06-21 2010-03-02 Institute Of Medicinal Molecular Design, Inc. N-(3,4-disubstituted phenyl) salicylamide derivatives
US8710068B2 (en) 2009-01-19 2014-04-29 The Trustees Of The University Of Pennsylvania Method of treating cancer using a survivin inhibitor
US9969751B2 (en) * 2009-06-10 2018-05-15 Techfields Pharma Co., Ltd. High penetration prodrug compositions of antimicrobials and antimicrobial-related compounds
CN101735113B (zh) * 2009-12-14 2014-03-19 南京大学 一类尿素衍生物及其制法与用途
MA39986A (fr) 2014-04-25 2017-03-01 Vitae Pharmaceuticals Inc Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer
US9957393B2 (en) 2015-03-30 2018-05-01 Enzo Biochem, Inc. Monoazo dyes with cyclic amine as fluorescence quenchers
CN109776354B (zh) * 2019-01-04 2021-11-19 上海应用技术大学 一种二羟基苯甲酰腙类神经氨酸酶抑制剂及其制备和应用
CN109651189B (zh) * 2019-01-31 2021-11-19 上海应用技术大学 一种苯甲酰腙类神经氨酸酶抑制剂及其制备方法和用途
US11993775B2 (en) * 2020-07-27 2024-05-28 National Cheng Kung University Ubiquitin-specific peptidase 24 inhibitor, medicinal composition and method of delaying or reversing multidrug resistance in cancers using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597719A (en) * 1994-07-14 1997-01-28 Onyx Pharmaceuticals, Inc. Interaction of RAF-1 and 14-3-3 proteins
US5571825A (en) * 1995-03-31 1996-11-05 Warner-Lambert Company Method of selectively inhibiting prostaglandin G/H synthase-2
NZ332103A (en) 1996-03-20 2000-08-25 Nuchem Pharmaceuticals Inc Triphenyl methane compounds or analogues thereof where one or more of the phenyl groups is substituted and the tertiary carbon atom is replaced for sickle cell disease,
EP0818744A3 (de) * 1996-07-08 1998-07-08 Proteus Molecular Design Limited Verfahren zur Auswahl von Kandidat-Drogenverbindungen
EP0982991A1 (de) 1997-05-09 2000-03-08 Smithkline Beecham Corporation Beta lactame als antiproliferative stoffe
EP2196930B1 (de) 1998-07-01 2011-03-23 The Trustees of The University of Pennsylvania Hohlraum-induzierte allosterische Modifikation von intermolekularen Interaktionen und Verfahren zur Identifikation von Verbindungen, die diese bewirken
DE102005052912A1 (de) * 2005-11-03 2007-05-10 Henkel Kgaa Mittel zum Färben keratinhaltiger Fasern

Also Published As

Publication number Publication date
US20110312920A1 (en) 2011-12-22
AU762749B2 (en) 2003-07-03
US8785419B2 (en) 2014-07-22
CA2336361A1 (en) 2000-01-13
EP1091974A2 (de) 2001-04-18
US7653495B1 (en) 2010-01-26
EP2196930B1 (de) 2011-03-23
US20100151507A1 (en) 2010-06-17
EP1091974A4 (de) 2005-06-15
JP4401025B2 (ja) 2010-01-20
JP2002519680A (ja) 2002-07-02
WO2000001349A2 (en) 2000-01-13
US8019557B2 (en) 2011-09-13
AU4730899A (en) 2000-01-24
EP1091974B1 (de) 2010-06-02
ATE503231T1 (de) 2011-04-15
WO2000001349A3 (en) 2000-11-09
ATE470195T1 (de) 2010-06-15
CA2336361C (en) 2011-09-06
EP2196930A1 (de) 2010-06-16
DE69943308D1 (de) 2011-05-05

Similar Documents

Publication Publication Date Title
DE69942454D1 (de) Hohlraum-induzierte allosterische modifikation von intermolekularen interaktionen und verfahren zur identifikation von verbindungen, die diese bewirken.
ATE373282T1 (de) Verfahren und vorrichtung zur tintenstrahlaufzeichnung
ATE269295T1 (de) Btk inhibitoren und verfahren zur identifizierung und verwendung
BRPI0415409A (pt) uso de efetuadores de ciclases de glutaminila e glutamato
DE69942742D1 (de) Immuntherapeutische zusammensetzung und verfahren zur behandlung von prostatakrebs
DE60027732D1 (de) Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems
DE60232522D1 (de) Verfahren zur vorhersage der behandlungsresultate
DE60035163D1 (de) Abc1 polypeptide und verfahren und reagenzien zur modulation des cholesterolgehalts
ATE520466T1 (de) Apparat und verfahren zur modifizierung von magnetisch inmmobilizierte biomolekulen
BRPI0407207A (pt) Método para tratar, prevenir e diagnosticar uma infecção por heliocobacter
DE602005017781D1 (de) Rekonstituierter histon-methyltransferase-komplex und verfahren zur identifizierung von modulatoren dafür
ATE203545T1 (de) Substrate und inhibitoren von proteolytischen enzymen
ATE271555T1 (de) Verfahren zur herstellung und screening von inhibitoren des bakteriellen nad synthetase enzyms, verbindungen daraus und methoden zur behandlung bakterieller und mikrobieller infektionen mit diesen inhibitoren
ATE212065T1 (de) Nukleinsäuremoleküle mit der fähigkeit zur unterscheidung von prpc und prpsc-prionprotein- isoformen und verfahren zu deren herstellung
DE602004021574D1 (de) Modulatorische verbindungen und verfahren für glutamattransport
ATE226254T1 (de) Reagenz zur behandlung von arthritischen zustaenden
PT865609E (pt) Processos para o diagnostico e terapia de carcinomas do epitelio escamoso
CA2353048A1 (en) Pharmaceutical composition useful in the prevention or treatment of peptic ulcers
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE69626522D1 (de) Peptide mit pronociceptiveigenschaften
ATE221784T1 (de) Arzneimittel zur heilung von thrombozytopenie
ATE219099T1 (de) Verfahren zur identifizierung von verbindungen, die zur behandlung von autoimmunkrankheiten verwendbar sind
ATE426812T1 (de) Verfahren zur diagnose und behandlung durch bindung von p75/airm1
DE60137459D1 (de) Verfahren und zusammensetzungen zur behandlung oder prävention von bakteriellen infektionen
ATE224387T1 (de) N-(pyridinylamino)isoindoline und verwandte verbindungen